Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of NN1731 in healthy volunteers to inform future development.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorder

Drugs mentioned

• NN1731

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Healthy | Phase 1 | Status: COMPLETED | Results posted: 2014-09-23